Cargando…
Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
We herein report the case of a 57-year-old woman presenting with a biopsy-proven tumefactive demyelinating lesion as her first clinical event. Subsequently, she displayed a relapsing-remitting course with recurrence of large demyelinating lesions exceeding 2 cm in diameter rather than the small ovoi...
Autores principales: | Nakamura, Masataka, Itani, Kumi, Miyake, Kousuke, Kunieda, Takenobu, Kaneko, Satoshi, Kusaka, Hirofumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337470/ https://www.ncbi.nlm.nih.gov/pubmed/28090055 |
Ejemplares similares
-
Thymoma-associated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM) with Myasthenia Gravis
por: Morise, Satoshi, et al.
Publicado: (2017) -
Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007) -
Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013) -
A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019) -
A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)